ArticleAmerican journal of translational research2025
Clinical effectiveness of Anlotinib combined with PD-1 inhibitors in treating advanced non-small-cell lung carcinoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical effectiveness of combining Anlotinib (ANB) and programmed death-1 receptor (PD-1) inhibitors in treating advanced non-small-cell lung carcinoma (aNSCLC) patients.
methodsThe study included 400 aNSCLC patients treated at Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine between January 2021 and June 2024. The control group (192 cases) received PD-1 inhibitor therapy, while the observation group (208 cases) received ANB + PD-1 inhibitor therapy. Comparative analyses were conducted between the two groups regarding clinical effectiveness, safety (nausea and vomiting, hand-foot syndrome, fatigue, decreased appetite, and anemia), coagulation function (thrombin time [TT], activated partial thromboplastin time [APTT], and fibrinogen [FIB]), serum biochemical indices (vascular endothelial growth factor [VEGF] and matrix metalloproteinase-2 [MMP-2]); immune function (immunoglobulin G/A/M (IgG/IgA/IgM)), serum tumor markers (carcinoembryonic antigen [CEA], carbohydrate antigen 125 [CA125], and cytokeratin 19 fragment antigen [CYFRA21-1]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), and short-term prognosis (Karnofsky Performance Status Scale [KPS]). Binary logistic regression was used to identify risk factors affecting clinical effectiveness and short-term prognosis.
resultsThe observation group showed significantly higher objective response and disease control rates compared to the control group (P < 0.001). Treatment modality was identified as a risk factor for clinical effectiveness (P < 0.001). Adverse reaction incidence was comparable between the groups (all P > 0.05), except for grade III-IV hand-foot syndrome and decreased appetite. TT showed no significant differences within or between groups (P > 0.05), but APTT and FIB increased significantly after treatment in the observation group, surpassing the control group (all P < 0.05). VEGF and MMP-2 levels decreased significantly after treatment in the observation group, with values lower than in the control group (P < 0.05). IgG, IgA, and IgM levels were markedly higher in the observation group after treatment, with improved PSQI and KPS scores compared to the control group (all P < 0.05). Serum tumor markers (CEA, CA125, CYFRA21-1) also decreased significantly in the observation group (all P < 0.05). VEGF was identified as a risk factor for short-term prognosis (P = 0.047).
conclusionThe combination of ANB and PD-1 inhibitors demonstrates significant effectiveness in aNSCLC patients, improving coagulation function, serum biochemical indices, immune function, sleep quality, and short-term prognosis without markedly increasing adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.